Comparator-dependent evidence for earlier PSMA-targeted radioligand therapy in prostate cancer: a systematic review and meta-analysis of randomized trials
This systematic review and meta-analysis of 12 randomized trials demonstrates that the efficacy of PSMA-targeted radioligand therapy in prostate cancer is primarily determined by the comparator agent rather than the disease line, supporting its use after androgen receptor pathway inhibitor progression but not as a replacement for docetaxel.